Article

bizjournals.com on 2022-07-05 17:10

FDA rejects NRx Pharmaceuticals' emergency use request for its experimental Covid-19 treatment

FDA

Related news

FDA rejects AstraZeneca's experimental diabetes therapy bizjournals.com
FDA rejects Sunovion's experimental drug to treat Parkinson's bizjournals.com
FDA rejects NRx's breakthrough designation bid for experimental Covid-19 therapy; stock price falls bizjournals.com
Eton Pharmaceuticals announces FDA approval dailyherald.com
Veloxis Pharmaceuticals, Inc. v. FDA jdsupra.com
FDA Backs Experimental 'Female Viagra'huffingtonpost.com
Raleigh
NRx Pharmaceuticals stock jumps on positive development for its experimental Covid therapy bizjournals.com
NRx Pharmaceuticals' experimental Covid-19 therapy fails in late-stage testing; stock price nose-dives bizjournals.com
Vanda Pharmaceuticals hits another snag with FDA bizjournals.com
NRx Pharmaceuticals names new CEO bizjournals.com
FDA OKs experimental blood test for Zika The Salt Lake Tribune
Latin America , Switzerland , Texas , Florida , Puerto Rico
FDA skeptical of experimental ALS drug journalrecord.com
China , Silver Spring
AThe Latest: House rejects experimental drug bill apnewsarchive.com
FDA rejects Intarcia's drug pump bizjournals.com
Supernus Pharmaceuticals seeks FDA approval for ADHD drug bizjournals.com
ANI Pharmaceuticals secures FDA approval, launches delayed-release naproxen Star Tribune
East Windsor , Baudette
Continuous Manufacturing of Pharmaceuticals: FDA Wants to Hear from Industry jdsupra.com
MAerie Pharmaceuticals' stock set to selloff after FDA inspection delay marketwatch.com
FDA gives Vanda Pharmaceuticals three-year marketing exclusivity for Fanapt bizjournals.com
MAcadia Pharmaceuticals submits new FDA for Parkinson's psychosis drug marketwatch.com
Ardea